Boston Scientific (BSX) stock tests historical support, lowers 2026 adjusted EPS guidance to $3.28-$3.32 due to WATCHMAN device market slowdown
Boston Scientific (BSX) stock is currently trading around $49.01, retreating to its historical price range of $46.56 to $51.46, a range previously defended by buyers six times. However, management has lowered its adjusted earnings per share (EPS) guidance for fiscal year 2026 to $3.28-$3.32, primarily due to an unexpected sharp slowdown in its WATCHMAN heart device in the U.S. market and increased competition in its electrophysiology (EP) business. The company anticipates limited adjusted EPS growth in 2027, hoping for a rebound driven by new products in 2028.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
Financial Times: Five Signals Warning of Approaching AI Bubble and US Debt Crisis
-
2
Societe Generale Bear Warns: AI Boom Replicating Asian Financial Crisis, Debt a "Ticking Time Bomb"
-
3
According to Bloomberg Markets: Large asset managers are deleveraging in the U.S. Treasury futures market, triggered by forced selling as cash yields approach multi-year highs.
-
4
Ethereum whales were liquidated for 28,716 ETH, worth nearly $70 million.
-
5
The DXY recorded its longest winning streak since early 2025, rising nearly 3% this week.
-
6
Wall Street's Rate Shock Spreads Beneath AI-Fueled Market Rally, Driven by High Oil Prices and Borrowing Costs
-
7
China State Funds Double Down on Hua Hong with $2.9 Billion Injection to Boost Legacy Chip Production
-
8
TypeSafe AI, the maker of the non-text AI model Jev, reached a valuation of $7.5 billion just weeks after its launch, with a16z leading an $870 million funding round.
-
9
LAUNCHCOIN: Solana Ecosystem's "One-Click Token Issuance" Platform Analysis and Market Status
-
10
European bond turbulence sparks debate over ECB repo funding
Markets Today
Recommended Reading



